Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib, Dexamethasone, and Rituximab in Waldenstrom's Macroglobulinemia
NCT00250926Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2005
- Primary completion
- Mar 2007
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in Waldenstrom macroglobulinemia (WM), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Number of Participants With Adverse Events at 33.2 months, Response Rate at 33.2 months and 2 more. Started Oct 2005; status: completed.
02
Drugs
bortezomib
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT00250926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00250926.